Secondly, the specific functional differences of AMPK isoforms (α1/α2, β1/β2, γ1/γ2/γ3) in the pathological process of NAFLD remain unclear, and isoform-selective regulation may become a key breakthrough for precise treatment. This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatotic liver disease.